Alertas Bibliográficas


DIABETES

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR, Bode B, Mertens A, Cho YM, Christiansen E, Hertz CL, Wallenstein SOR, Buse JB, PIONEER 7 investigators.
Lancet Diabetes Endocrinol. 2019 Jul;7(7):528-539.
http://doi.org/10.1016/S2213-8587(19)30194-9

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Diabetes Care. 2019 Aug;42(8):1593-1603.
http://doi.org/10.2337/dci19-0028


ENDOCRINOLOGÍA

Immune check point inhibitors-induced hypophysitis Frédérique Albarel1,2, Frédéric Castinetti1,2 and Thierry Brue1,2
European Journal of Endocrinology (2019) 181, R107–R118
https://doi.org/10.1530/EJE-19-0169


PEDIATRÍA

Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Goedegebuure WJ, Hokken-Koelega ACS.
Horm Res Paediatr. 2019 Aug 7:1-5.
http://doi.org/10.1159/000501746

Multicentre study of maternal and neonatal outcomes in individuals with Prader-Willi syndrome.
Singh P, Mahmoud R, Gold JA, Miller JL, Roof E, Tamura R, et al.
J Med Genet. 2018 May 18. pii: jmedgenet-2017-105118.
http://doi.org/10.1136/jmedgenet-2017-105118


CIENCIAS BÁSICAS

Effect of Iodothyronines on Thermogenesis: Focus on Brown Adipose Tissue.
Cioffi F, Gentile A, Silvestri E, Goglia F, Lombardi A.
Front Endocrinol (Lausanne). 2018 May 23;9:254.
http://doi.org/10.3389/fendo.2018.00254
eCollection 2018. Review. PubMed PMID: 29875734; PubMed Central PMCID: PMC5974034.